McGranahan et al. [49] found increased sensitivity to both PD-1 and CTLA-4 blockade, and improved overall survival (OS), among NSCLC and melanoma patients with tumors harboring low ITH and high clonal neoantigen burden. This evidence concerns the gene CTLA4 and melanoma.